Provention Bio (PRVB) Releases Quarterly Earnings Results

Share on StockTwits

Provention Bio (NASDAQ:PRVB) released its quarterly earnings results on Thursday. The company reported ($0.17) EPS for the quarter, Morningstar.com reports.

Shares of PRVB traded down $0.02 during mid-day trading on Friday, hitting $3.16. 21,053 shares of the company traded hands, compared to its average volume of 51,935. Provention Bio has a 1-year low of $2.52 and a 1-year high of $8.00.

An institutional investor recently bought a new position in Provention Bio stock. Dean Capital Investments Management LLC acquired a new stake in shares of Provention Bio Inc (NASDAQ:PRVB) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned approximately 0.12% of Provention Bio as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “Provention Bio (PRVB) Releases Quarterly Earnings Results” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3929238/provention-bio-prvb-releases-quarterly-earnings-results.html.

Provention Bio Company Profile

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

Further Reading: Diversification in Investing

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Toronto Dominion Bank Trims Stake in HP Inc.
Toronto Dominion Bank Trims Stake in HP Inc.
Air Products & Chemicals, Inc.  Shares Bought by Toronto Dominion Bank
Air Products & Chemicals, Inc. Shares Bought by Toronto Dominion Bank
Sterling Consolidated  and EnPro Industries  Head-To-Head Survey
Sterling Consolidated and EnPro Industries Head-To-Head Survey
Ameriprise Financial, Inc.  Stake Lifted by Sumitomo Mitsui Trust Holdings Inc.
Ameriprise Financial, Inc. Stake Lifted by Sumitomo Mitsui Trust Holdings Inc.
Toronto Dominion Bank Reduces Stake in Oracle Co.
Toronto Dominion Bank Reduces Stake in Oracle Co.
Analyzing China Ceramics  and OLYMPUS Corp/S
Analyzing China Ceramics and OLYMPUS Corp/S


Leave a Reply

© 2006-2018 Ticker Report